mediri GmbH’s Post

Our last work 👇🏻 Cervical cancer (CC) represents a significant health concern worldwide, particularly for younger women. Cold knife (CK) conization and carbon dioxide (CO2) laser conization are two techniques commonly used to remove pre-invasive lesions, offering a potential curative intent in cases of incidental diagnosis of CC. This study aimed to assess the clinical implications and pathological outcomes of CK vs. CO2 laser conization for pre-invasive lesions. We retrospectively analyzed women who underwent CO2 or CK conization for high-grade preinvasive lesions (CIN2/3, CIS and AIS) between 2010 and 2022. Patient demographics, surgical details and pathological outcomes were collected. Pregnancy outcomes, including composite adverse obstetric rates, and oncological follow-up data, were also obtained. In all, 1270 women were included; of them, 1225 (96.5%) underwent CO2, and 45 (3.5%) underwent CK conization. Overall, the rate of positive endocervical or deep margins was lower with CO2 laser compared to CK (4.3% vs. 13.3%, p = 0.015). Incidental CC was diagnosed in 56 (4.4%) patients, with 35 (62.5%) squamous and 21 (46.6%) adenocarcinomas. In a multivariate regression model, the relative risk for positive endocervical or deep margins is significantly greater in cases of incidental diagnosis of CC (p < 0.01). In cases of incidental diagnosis of CC, we found that the probabilities of having either positive endocervical or deep margins after CO2 laser or CK conization are similar, with a higher risk in case of adenocarcinoma lesion. Among women with CC, 42 (75%) opted for radical treatment, while 14 (25%) underwent a follow-up. Only one woman (7.1%) in the follow-up group, who had undergone CK conization, experienced a composite adverse obstetric outcome. No recurrences were observed after a median follow-up of 53 months. CO2 laser conization achieved a lower positive margin rate overall. CK and CO2 conization appear to be equivalent oncological options for incidental CC.

#ICYMI… How can Ancient Chinese traditional #medicine significantly reduce the side effects of #rectalcancer treatment? Senior author Susan Higgins, MD, professor of therapeutic radiology and obstetrics, gynecology, and reproductive sciences, and her team discuss their findings published in the Journal of Gastrointestinal Oncology. Read the article by Mike Masciadrelli to learn more ⬇ Yale School of Medicine

Clarivate has announced the 2023 Journal Impact Factors and we are delighted to see the results for our journals. Some notable mentions: 🌟 EFORT Open Reviews has achieved a 2023 Journal Impact Factor of 4.3. The journal has climbed to number 10 of 136 journals in the ‘Orthopedics’ category. 🌟 Reproduction has achieved a 2023 Journal Impact Factor of 3.7, placing it at number 7 of 39 journals in the ‘Reproductive Biology’ category, and making it a Q1 journal. 🌟 Reproduction and Fertility has achieved a 2023 figure of 2.8. It is ranked number 16 of 39 in the ‘Reproductive Biology’ category in the latest Journal Citation Reports. 🌟 Endocrine-Related Cancer now has a Journal Impact Factor of over 4 after securing a 2023 figure of 4.1 and is in the second quartile. 🌟 Journal of Molecular Endocrinology has achieved a 2023 Journal Impact Factor of 3.6 and is in the second quartile. Find out more about our results in our latest press release: https://lnkd.in/dKUN6PKw

bFGF and Fertility in women 15 July 2024 I was recently asked by Dr Jones in Texas if basic Fibroblast Growth Factor (bFGF) can be applied to the fallopian tubes as a therapeutic agent aimed at promoting tissue repair and regeneration. bFGF is not approved for the application of bFGF, but bFGF involves several potential methods: 1.      Direct Instillation: Similar to the G-CSF instillation procedure used in fertility treatments, bFGF can be directly instilled into the uterine cavity or the fallopian tubes through a thin catheter. This method ensures that the growth factor reaches the targeted area where it can stimulate cellular repair and regeneration processes[4]. 2.      Hydrotubation: This procedure involves flushing the fallopian tubes with a solution containing bFGF. Hydrotubation helps to clear blockages and can deliver the growth factor directly to the damaged areas, promoting healing and improving the chances of natural conception[2]. 3.      Microsurgical Techniques: During laparoscopic surgery, bFGF can be applied to the fallopian tubes to enhance the healing of tissues after surgical interventions aimed at removing obstructions or repairing damage. This targeted approach can improve surgical outcomes and tubal patency[5]. 4.      Endoscopic Application: Endoscopic procedures such as hysteroscopy or laparoscopy can be used to apply bFGF directly to the fallopian tubes. These minimally invasive techniques allow for precise delivery of the growth factor to the areas needing repair, thus promoting better recovery and function of the tubes[6]. These methods highlight the versatility of bFGF application in treating fallopian tube-related infertility by leveraging its regenerative properties to improve tissue health and function. mdpi.com - Application of Stem Cell Therapy for Infertility ncbi.nlm.nih.gov - A systematic review and meta-analysis - PMC varta.org.au - Study confirms 'flushing' blocked fallopian tubes can improve fertility fertilitynorth.com.au - G-CSF Instillation Procedure (GIP) webmd.com - What fallopian tube procedures help with fertility? carefertility.com.au - Evaluation of the fallopian tubes

Our article entitled: "Single dominant lesion in capillary malformation-arteriovenous malformation (CM-AVM) RASA1 syndrome" is now published in the journal of Pediatric Dermatology. Our study underscores the rarity of somatic RASA1 variants, contributes to understanding (and bridges the gap) the “second-hit” pathophysiology of vascular lesions, and emphasizes the significance of clinical distinctions and genotyping for accurate diagnoses, offering implications for diagnosis, prognosis, and genetic counseling to the patients and their families. #vascularanomalies #vascularmalformations #ISSVA #RASA1gene #somaticmutation #CMAVMsyndrome #pediatricdermatology The open access link is available here:

Adenomyosis is an important clinical condition with an uncertain prevalence, and during recent years clinical focus on the adenomyosis - ART patient has increased. Recognizing the limited clinical knowledge on the impact of adenomyosis on ART outcomes, “The First Lugano Adenomyosis Workshop “aimed to organize a symposium with experts in the field of adenomyosis, covering basic research, imaging, surgery and infertility to highlight current advances and future research areas over a wide range of topics related to adenomyosis. The outcomes of this workshop are presented in this new Review article, authored by Mauro Cozzolino, Serdar Bulun, Dominique de Ziegler, Caterina Exacoustos, Human M. Fatemi,MD,PhD, Juan A. García Velasco, Andrew Horne, Felice Petraglia, Pietro Santulli, Edgardo Somigliana, Kim Soorin, Thierry Van den Bosch, Paola Viganò, and Peter Humaidan. The authors suggest three main goals that should be pursued during the next decade: First, the type of adenomyosis which interferes with embryo implantation or other reproductive outcomes must be clarified. Studies should not focus exclusively on implantation, but also on other reproductive outcomes, including miscarriage and obstetrics complications. Second, the most suitable therapeutical approach to be used in ART for adenomyosis needs to be explored. Although evidence is emerging on the efficacy of using freeze-all strategies, protracted hormonal suppressive treatments, and tailored and high-dose progesterone in adenomyosis, the quality of the evidence is still weak and RCTs are warranted. Third, and most ambitiously, the pathogenesis of the disease should be further clarified. This could open treatment options which could prevent the occurrence or spread of the disease. As with all RBMO Review articles, this paper is free to read, currently available as an early access pre-proof from our in-press articles: https://lnkd.in/eMkY66pP #RBMOreviews #FemaleReproductiveHealthAndFertility #Adenomyosis #Pathogenesis #Diagnosis #HormonalTreatment #SurgicalTreatment #ART

Opportunistic salpingectomy, at the time of non-gynecologic surgeries, is a promising strategy for reducing ovarian cancer risk, especially among average-risk women who have completed childbearing. Read the latest from the FIGO (International Federation of Gynecology and Obstetrics) Committee on Women's Cancer: https://lnkd.in/eDysFe3a

Dr. Brian Helfand, Endeavor Health's Chief of Urology, is leading the charge with aquablation therapy, offering hope to those battling benign prostatic hyperplasia (BPH). This state-of-the-art treatment stands out by being precisely tailored to each patient's anatomy, ensuring maximum effectiveness while preserving function and control—concerns often overlooked by traditional therapies. Learn more about this innovative treatment: https://bit.ly/49H29aE

Tippi MacKenzie, pioneering the future of surgery, foresees a world where scalpel-free procedures and gene editing prevent heritable diseases in fetuses. Megan Molteni delves into her mission, powered by #CRISPR, to intervene before genetic conditions cause irreversible damage. More in the STAT article titled “Meet the fetal surgeon forging CRISPR’s next frontier: curing diseases in the womb” https://lnkd.in/eUEMmdan #FetalSurgery #GeneEditing

Gynecology 2024: New Perspectives and Innovations in Women's Health In recent years, gynecology has undergone significant changes thanks to the development of technology and scientific discoveries. In 2024, even more innovations are expected that will help improve the diagnosis, treatment, and overall health of women. In this article, we will discuss some of the anticipated new perspectives and methods that will transform gynecological practice. One of the most exciting new technologies expected in gynecology in 2024 is the advancement and application of artificial intelligence (AI). Artificial intelligence can help automate and enhance the diagnosis of various conditions, as well as predict the risk and effectiveness of treatment. With AI, doctors will be able to more accurately identify early signs of cervical cancer, breast cancer, and other gynecological diseases, leading to earlier treatment initiation and increased chances of survival. Another promising area in gynecology in 2024 is the use of genetic testing. Genetic tests are becoming increasingly accessible and informative, allowing doctors to assess the risk of developing genetically predisposed conditions in women and their offspring. This aids in making more accurate decisions about treatment and preventing the development of diseases. In 2024, there is also an expected development of new diagnostic methods such as computed tomography (CT) and magnetic resonance imaging (MRI). These methods provide more detailed images of internal organs and tissues, aiding in the diagnosis of tumors, cysts, inflammatory processes, and other conditions. The development of 3D ultrasound is also anticipated, which will provide three-dimensional images of organs and tissues, improving the diagnosis of the structure of the uterus, ovaries, and other organs. One of the most exciting innovations in gynecology in 2024 is the use of robotic technology for biopsies. Robotic biopsies allow doctors to accurately and safely obtain tissue samples from various organs for further analysis and disease diagnosis. This significantly improves diagnostic accuracy and enables earlier treatment initiation. In conclusion, gynecology in 2024 represents a field of rapid advancement and innovation. With the integration of artificial intelligence, genetic testing, advanced imaging techniques, and robotic technology, the future of gynecological practice promises improved diagnosis, treatment, and overall women's health.